BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCTX): 9 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.7 months
0% dilution
Lead: Phase 3
9 candidates
1 upcoming, next in ~714d
N/A
A transparent, data-derived signal for BriaCell Therapeutics Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$24.3M
Cash
$6.9M
Quarterly Burn
$7.0M
Runway
9.7 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| Bria-IMT™ | Phase 3 |
| Bria-OTS+™ | — |
| Bria-OTS™ | — |
| Bria-PROS+™ | — |
| interferon infiltration of the inoculation site | Phase 3 |
| interferon inoculation | Phase 3 |
| retifanlimab | Phase 3 |
| sv-br-1-gm | Phase 3 |
| treatment of physician's choice | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$662K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 73,915 | $310K |
| iridian asset management llc/ct | 65,000 | $272K |
| luminarx capital management lp | 15,000 | $63K |
| morgan stanley | 3,021 | $13K |
| national bank of canada /fi/ | 802 | $3K |
| federation des caisses desjardins du quebec | 455 | $2K |
| td waterhouse canada inc. | 19 | $78 |
| group one trading llc | 16 | $67 |
| caitong international asset management co., ltd | 7 | $29 |
| hhm wealth advisors, llc | 6 | $26 |
Showing top 10 of 12 institutional holders of BriaCell Therapeutics Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BriaCell Therapeutics Corp.'s pipeline?
BriaCell Therapeutics Corp. (BCTX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BriaCell Therapeutics Corp.'s lead drug candidate?
BriaCell Therapeutics Corp.'s most advanced tracked candidate is Bria-IMT™ (Phase 3) for Treatment of metastatic breast cancer (MBC); treatment of patients with MBC who have failed prior lines of therapy and who have no approved alternative therapies available..
What is BriaCell Therapeutics Corp.'s next catalyst?
BriaCell Therapeutics Corp.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice" — expected June 1, 2028.
What is BriaCell Therapeutics Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BriaCell Therapeutics Corp. has approximately 9.7 months of cash runway.
What is BriaCell Therapeutics Corp.'s market capitalization?
BriaCell Therapeutics Corp.'s market capitalization is approximately $24.3M.
Get the full picture on BriaCell Therapeutics Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.